| Name | Drotaverine hydrochloride |
| Description | Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor,and is an antispasmodic drug, used to enhance cervical dilation during childbirth. Drotaverine hydrochloride is structurally related to papaverine |
| In vitro | drotaverine not only relaxed the precontracted tracheal preparations but also decreased mediator-induced contraction.?These effects of drotaverine were concentration dependent, with a significantly higher potency on the KCl-induced response, than on either the histamine or methacholine induced one.?A similar result was noted for nifedipine.?The PDE inhibitor, theophylline, also relaxed the precontracted preparations but was ineffective on the mediator-induced contraction in a physiologically relevant concentration range. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 25 mg/mL (57.61 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.61 mM), Sonication is recommended.
|
| Keywords | Phosphodiesterase (PDE) | PDE4 | Inhibitor | inhibit | Drotaverine hydrochloride | Drotaverine | Calcium Channel | Ca2+ channels | Ca channels |
| Inhibitors Related | Quadrol | 2,4,6-Tri-tert-butylphenol | Balipodect | Chlorocresol | L-Ascorbic acid | D(+)-Raffinose pentahydrate | Indomethacin | L-Ascorbic acid sodium salt | 2-Nitrobenzoic acid | Magnesium Chloride Hexahydrate | Sildenafil citrate | Magnesium sulfate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Cardiovascular Disease Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Human Metabolite Library |